FDA Ketoacidosis Warning Provides Support For Invokana Lawsuit Plaintiff Allegations

March 28, 2016 – – TheProductLawyers.com reports on several lawsuits recently filed against Janssen Pharmaceuticals (a division of corporate giant Johnson & Johnson). The lawsuit plaintiffs allege that Janssen, who manufactures new-generation, type-2 diabetes drug Invokana, has potentially downplayed some dangerous side effects linked to the drug. These revelations now combine with an announcement from the U.S. Food and Drug Administration which indicated the requirement of new label warnings for the drug.

Warnings are reported to discuss a potentially life-threatening condition which several Invokana plaintiffs have also mentioned called diabetic ketoacidosis. Diabetic ketoacidosis develops when a body’s bloodstream contains too much toxic acid (or ketones). This condition has been reported to the FDA through adverse event reports involving patients taking Invokana who have allegedly developed it.

The warning information that comes on Invokana packaging discusses multiple side effects including low blood pressure and blood infections, diabetic ketoacidosis, kidney disease and infections, bone fractures and lowered bone density, urinary tract infections and yeast infections, and high cholesterol levels. Reportedly, the FDA decided that the current warnings needed to be revised and announced this decision in December of 2015.

Before this announcement, the FDA released a public safety warning concerning diabetic ketoacidosis in May of 2015. The release of this warning reportedly followed 73 adverse event reports involving ketoacidosis development among patients using either Invokana or similar SGLT2 class inhibitor drugs. It was noted that some patients reported that these side effects were experienced in as little as 3 months after beginning use of the drug.

The attorneys of Banville Law understand how concerning these potential side effect links are for patients currently depending upon Invokana or similar drugs. They are dedicated to updating the public with the latest important information surrounding these drugs and others, and sponsor the online resource TheProductLawyers.com for this purpose. In addition, the attorneys of Banville Law are working to help patients who have taken SGLT2 inhibitor drugs and who also suffered from health problems that they attribute to this drug use. They want to help ensure that affected individuals will be provided with an opportunity to fully investigate their legal rights in the matter. These patients may be entitled to significant compensation. To help those wishing to pursue legal action, the attorneys of Banville Law are offering complimentary legal consultations to affected individuals at this time.

To request further information, or to ask questions regarding Invokana lawsuits, please contact Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60008912